SPECIFIC BLOCK OF THE ANTIISCHEMIC ACTIONS OF CROMAKALIM BY SODIUM 5-HYDROXYDECANOATE

被引:151
作者
MCCULLOUGH, JR [1 ]
NORMANDIN, DE [1 ]
CONDER, ML [1 ]
SLEPH, PG [1 ]
DZWONCZYK, S [1 ]
GROVER, GJ [1 ]
机构
[1] BRISTOL MYERS SQUIBB INST PHARMACEUT RES,DEPT PHARMACOL,POB 4000,PRINCETON,NJ 08543
关键词
ISCHEMIA; POTASSIUM CHANNEL MODULATORS; CROMAKALIM; GLIBENCLAMIDE;
D O I
10.1161/01.RES.69.4.949
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The potassium channel activators cromakalim and pinacidil were recently shown to have anti-ischemic properties in isolated globally ischemic rat hearts. The effects of two reported blockers of ATP-sensitive potassium channels, glibenclamide (glyburide) and sodium 5-hydroxydecanoate, on the anti-ischemic efficacy of cromakalim were determined in this model. Buffer-perfused rat hearts were subjected to 25 minutes of ischemia followed by 30 minutes of reperfusion. Pretreatment of these hearts with 60-mu-M cromakalim significantly decreased indexes of contractile function but caused a significant improvement of postreperfusion function and a significant decrease in release of lactate dehydroxygenase and in end-diastolic pressure. Pretreatment with glibenclamide at concentrations that reversed the preischemic effects of cromakalim (0.05 and 1.0-mu-M) also significantly reversed its postischemic protective effects. Sodium 5-hydroxydecanoate (100 and 300-mu-M) had no effect on the preischemic (negative inotropic) effects of cromakalim but completely reversed its cardioprotective effects. Sodium 5-hydroxydecanoate did not reverse the cardioprotective effects of the calcium entry blocker diltiazem. In phenylephrine-contracted rat aorta, glibenclamide (0.1-10-mu-M) inhibited cromakalim-induced relaxation, whereas sodium 5-hydroxydecanoate (10-1,000-mu-M) had no effect. Similarly, the ability of cromakalim to shorten cardiac action potential duration in guinea pig papillary muscle and to increase outward whole-cell potassium currents in isolated myocytes was inhibited by glibenclamide, whereas sodium 5-hydroxydecanoate was without effect. Thus, both glibenclamide and sodium 5-hydroxydecanoate inhibited the effects of cromakalim after reperfusion; however, sodium 5-hydroxydecanoate, unlike glibenclamide, had no effect in nonischemic preparations. These results suggest that sodium 5-hydroxydecanoate is an ischemia-selective inhibitor of ATP-sensitive potassium channels.
引用
收藏
页码:949 / 958
页数:10
相关论文
共 24 条
[2]   THE POTASSIUM CHANNEL OPENER CROMAKALIM (BRL-34915) ACTIVATES ATP-DEPENDENT K+ CHANNELS IN ISOLATED CARDIAC MYOCYTES [J].
ESCANDE, D ;
THURINGER, D ;
LEGUERN, S ;
CAVERO, I .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 154 (02) :620-625
[3]  
FOSSET M, 1988, J BIOL CHEM, V263, P7933
[4]   A CA-2+-ACTIVATED K+ CHANNEL FROM RABBIT AORTA - MODULATION BY CROMAKALIM [J].
GELBAND, CH ;
LODGE, NJ ;
VANBREEMEN, C .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 167 (02) :201-210
[5]  
GELBAND CH, 1989, PHYSIOLOGIST, V32, P209
[6]  
GROVER GJ, 1989, J PHARMACOL EXP THER, V251, P98
[7]   PHARMACOLOGICAL PROFILE OF CROMAKALIM IN THE TREATMENT OF MYOCARDIAL-ISCHEMIA IN ISOLATED RAT HEARTS AND ANESTHETIZED DOGS [J].
GROVER, GJ ;
SLEPH, PG ;
DZWONCZYK, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 16 (06) :853-864
[8]   REDUCTION OF ISCHEMIC DAMAGE IN ISOLATED RAT HEARTS BY THE POTASSIUM CHANNEL OPENER, RP-52891 [J].
GROVER, GJ ;
DZWONCZYK, S ;
SLEPH, PG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 191 (01) :11-18
[9]  
GROVER GJ, 1989, CIRCULATION, V80, P499
[10]  
HAMILTON TC, 1989, GEN PHARMACOL, V21, P1